Dr Reddy's announces launch of dimethyl fumarate capsules in US
28 September 2020 | News
Dimethyl fumarate delayed-release capsules, a therapeutic equivalent generic version of Tecfidera®
Image source: Shutterstock
Hyderabad based Dr Reddy’s Laboratories Ltd., along with its subsidiaries together referred to as (“DrReddy’s”) have recently announced the launch of Dimethyl Fumarate Delayed-Release Capsules, a therapeutic equivalent generic version of Tecfidera® (dimethyl fumarate) Delayed-Release Capsules, approved by the US Food and Drug Administration (USFDA).
The Tecfidera® brand and the generic market had U.S. sales of approximately $3.8 billion MAT for the most recent twelve months ending in June 2020 according to IQVIA Health*.
Dr Reddy’s dimethyl fumarate delayed-release capsules are available in 120 mg and 240 mg. Tecfidera® is a trademark of Biogen.
